BrightPath Biotherapeutics Co., Ltd. 4594.T Stock
BrightPath Biotherapeutics Co., Ltd. Price Chart
BrightPath Biotherapeutics Co., Ltd. 4594.T Financial and Trading Overview
| BrightPath Biotherapeutics Co., Ltd. stock price | 61 JPY |
| Previous Close | 136 JPY |
| Open | 136 JPY |
| Bid | 135 JPY x 0 |
| Ask | 137 JPY x 0 |
| Day's Range | 135 - 137 JPY |
| 52 Week Range | 61 - 270 JPY |
| Volume | 512.8K JPY |
| Avg. Volume | 1.47M JPY |
| Market Cap | 8.62B JPY |
| Beta (5Y Monthly) | 1.762452 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.13 JPY |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
4594.T Valuation Measures
| Enterprise Value | 473.37M JPY |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 32.884186 |
| Price/Book (mrq) | 1.0445735 |
| Enterprise Value/Revenue | 1.807 |
| Enterprise Value/EBITDA | -0.301 |
Trading Information
BrightPath Biotherapeutics Co., Ltd. Stock Price History
| Beta (5Y Monthly) | 1.762452 |
| 52-Week Change | 58.13% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 270 JPY |
| 52 Week Low | 61 JPY |
| 50-Day Moving Average | 149.8 JPY |
| 200-Day Moving Average | 129.17 JPY |
4594.T Share Statistics
| Avg. Volume (3 month) | 1.47M JPY |
| Avg. Daily Volume (10-Days) | 750.53K JPY |
| Shares Outstanding | 62.89M |
| Float | 39.71M |
| Short Ratio | N/A |
| % Held by Insiders | 2.40% |
| % Held by Institutions | 4.13% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2018 |
| Most Recent Quarter (mrq) | December 31, 2018 |
| Next Fiscal Year End | March 31, 2019 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -638.16% |
| Gross Margin | 44.27% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -20.56% |
| Return on Equity (ttm) | -38.43% |
Income Statement
| Revenue (ttm) | 262M JPY |
| Revenue Per Share (ttm) | 6.29 JPY |
| Quarterly Revenue Growth (yoy) | -81.20% |
| Gross Profit (ttm) | 38M JPY |
| EBITDA | -1575000064 JPY |
| Net Income Avi to Common (ttm) | -1871000064 JPY |
| Diluted EPS (ttm) | -28.9 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.23B JPY |
| Total Cash Per Share (mrq) | 124.72 JPY |
| Total Debt (mrq) | 0 JPY |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 42.336 |
| Book Value Per Share (mrq) | 131.154 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of BrightPath Biotherapeutics Co., Ltd.
| Country | Japan |
| State | N/A |
| City | Tokyo |
| Address | Kojimachi Central Building |
| ZIP | N/A |
| Phone | N/A |
| Website | https://www.brightpathbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 42 |
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan and internationally. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops iPS-NKT, a new allogeneic cancer immunotherapy using NKT cells redifferentiated from iPS cells; BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma; and BP1200, an antibody targeting CD73. In addition, the company is developing BP1202, a novel anti-tumor environment-improving and immune-stimulating antibody targeting CD39; BP1210, a novel immune checkpoint inhibitor; BP1212, a novel tumor-immune activating antibody that inhibits TIM-3 and CD39; and BP1209, a platform of personalized neoantigen cancer vaccines. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Q&A For BrightPath Biotherapeutics Co., Ltd. Stock
What is a current 4594.T stock price?
BrightPath Biotherapeutics Co., Ltd. 4594.T stock price today per share is 61 JPY.
How to purchase BrightPath Biotherapeutics Co., Ltd. stock?
You can buy 4594.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BrightPath Biotherapeutics Co., Ltd.?
The stock symbol or ticker of BrightPath Biotherapeutics Co., Ltd. is 4594.T.
Which industry does the BrightPath Biotherapeutics Co., Ltd. company belong to?
The BrightPath Biotherapeutics Co., Ltd. industry is Biotechnology.
How many shares does BrightPath Biotherapeutics Co., Ltd. have in circulation?
The max supply of BrightPath Biotherapeutics Co., Ltd. shares is 66.39M.
What is BrightPath Biotherapeutics Co., Ltd. Price to Earnings Ratio (PE Ratio)?
BrightPath Biotherapeutics Co., Ltd. PE Ratio is now.
What was BrightPath Biotherapeutics Co., Ltd. earnings per share over the trailing 12 months (TTM)?
BrightPath Biotherapeutics Co., Ltd. EPS is -19.13 JPY over the trailing 12 months.
Which sector does the BrightPath Biotherapeutics Co., Ltd. company belong to?
The BrightPath Biotherapeutics Co., Ltd. sector is Healthcare.